

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## Protocol for a Longitudinal Study into Physical Activity and Cardiovascular Risk in People with Stroke

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019193
Article Type:	Protocol
Date Submitted by the Author:	17-Aug-2017
Complete List of Authors:	Fini, Natalie; University of Melbourne, School of Health Sciences , Physiotherapy; Alfred Health, Physiotherapy Bernhardt, Julie; Florey Institute of Neuroscience and Mental Health - Austin Campus, Stroke Division Holland, Anne E.; Alfred Health, Physiotherapy; La Trobe University, Physiotherapy
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Cardiovascular medicine, Rehabilitation medicine
Keywords:	Stroke < NEUROLOGY, physical activity, cardiovascular risk, longitudinal

SCHOLARONE™  
Manuscripts

1  
2  
3 Title:  
4  
5

6 **Protocol for a Longitudinal Study into Physical Activity and Cardiovascular Risk in People**  
7  
8 **with Stroke**  
9

10  
11 Authors:  
12

13 **Natalie A. Fini**<sup>1, 2,3</sup>; Julie Bernhardt<sup>2, 4</sup>; Anne E. Holland<sup>2,5</sup>  
14  
15  
16

17 Affiliations:  
18

19 <sup>1</sup> Physiotherapy Department, Caulfield Hospital, Alfred Health  
20

21 <sup>2</sup> Physiotherapy Department, School of Allied Health, La Trobe University  
22

23 <sup>3</sup> Physiotherapy Department, Melbourne School of Health Sciences, The University of  
24 Melbourne  
25

26 <sup>4</sup> Stroke Division, Florey Institute of Neurosciences and Mental Health, The University of  
27 Melbourne  
28

29 <sup>5</sup> Physiotherapy Department, Alfred Health  
30  
31  
32

33 Contact Information:  
34

35 *Corresponding Author:*  
36

37 Natalie A. Fini  
38

39 Physiotherapy Department, Melbourne School of Health Sciences  
40

41 Level 7, 161 Barry St  
42

43 Alan Gilbert Building  
44

45 The University of Melbourne  
46

47 Parkville VIC 3010  
48

49 Australia  
50

51 Ph: +61 401 303 749; Fax: +61 3 8344 4188  
52

53 Email: [natalie.fini@unimelb.edu.au](mailto:natalie.fini@unimelb.edu.au)  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 Julie Bernhardt

8 Florey Institute of Neurosciences and Mental Health, The University of Melbourne

9 Heidelberg

10 Australia

11  
12  
13  
14  
15  
16  
17 Anne E. Holland

18 La Trobe University / Alfred Health

19 Melbourne

20 Australia

21  
22  
23  
24  
25  
26  
27 Key Words:

28 stroke, physical activity; cardiovascular risk, longitudinal

29  
30  
31  
32  
33  
34  
35  
36 Word Count:

37 2269 words including abstract

**ABSTRACT****Introduction:**

Physical activity (PA) can modify cardiovascular and other health risks in people with stroke, but we know little about long term PA in this group. This study aims to describe PA levels and investigate relationships between PA, cardiovascular risk, mobility and participant characteristics (eg. age, mood and fatigue) in the two years following rehabilitation discharge after first stroke.

**Methods and Analysis**

This is a longitudinal observational study with follow up at six, 12, and 24 months after rehabilitation discharge. Inclusion criteria are broad; excluding only those with previous stroke, a palliative diagnosis, living more than two hours from the centre or admitted less than five days.

The primary outcome of interest is duration of moderate-vigorous PA (minutes/day) measured by the Sensewear MF Armband (SWAB). Secondary outcomes include other PA measures measured with the SWAB; cardiovascular risk factors (eg. systolic blood pressure, fasting lipid profile, smoking status), mobility (10 metre walk test), the Hospital Anxiety and Depression Scale and the Fatigue Severity Scale. All outcomes, except blood tests are gathered at each time point.

1  
2  
3 The target sample size is 77. We will explore associations between PA levels, cardiovascular  
4 risk factors, mobility and participant characteristics at baseline compared to 12 and 24  
5  
6  
7 months using random effects regression modelling.  
8  
9

10  
11  
12 The long term PA of stroke survivors is largely unknown. We hope to identify factors that  
13 influence PA and cardiovascular risk in this population, which may help health professionals  
14 to target the stroke survivors most at risk and implement appropriate treatment,  
15  
16  
17 preventative strategies and education.  
18  
19  
20  
21  
22

### 23 24 25 26 **Ethics and Dissemination** 27

28  
29 Approval was granted from Alfred Hospital and La Trobe University Research Ethics  
30 Committees. The study results will be disseminated in a number of ways including journal  
31 publication and international conference presentations. This study is registered with the  
32  
33  
34 Australian New Zealand Clinical Trials Registry (ACTRN12613000196741).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Strengths and Limitations of this Study:**

#### **Strengths:**

- This study will be the largest longitudinal PA dataset from stroke survivors to date.
- Investigates the important issues of secondary prevention and cardiovascular risk after stroke.
- Measures a number of physical activity outcomes objectively using a device that has been validated in stroke survivors.

#### **Limitations:**

- It is a relatively small, single centre study.
- Does not measure PA in the acute phase after stroke.

## INTRODUCTION AND RATIONALE

The importance of physical activity (PA) for cardiovascular health is well documented<sup>1-3</sup> and the detrimental effects of sedentary behaviour are substantial.<sup>4-6</sup> Physical activity guidelines for healthy individuals state that 30 minutes of moderate to vigorous intensity PA (MVPA) should be undertaken five days per week.<sup>7</sup> Adherence to these guidelines is associated with a 14% relative risk reduction in all-cause mortality.<sup>8</sup> To achieve cardiovascular benefits, it is recommended that MVPA be accumulated in bouts of at least 10 minutes.<sup>9</sup> Long bouts of uninterrupted sitting are associated with an increased rate of cardiovascular and all-cause mortality in healthy populations.<sup>5,6</sup> Recommendations about breaking up sitting time have been highlighted in government documents and recommendations internationally.<sup>10-12</sup> Increasing PA and reducing sedentary behaviour are now global targets for better health in a wide range of populations.

Stroke is a major cause of disability worldwide.<sup>13</sup> Mobility limitations are common following a stroke<sup>14</sup> and are associated with poor participation in PA and higher levels of sedentary behaviour than community-dwelling older adults.<sup>15</sup> Depression and fatigue, common in stroke, are also associated with lower PA.<sup>16,17</sup> Almost one third of stroke patients will suffer another stroke within five years<sup>18,19</sup> and 50% of people who survive 5-10 years will die of recurrent stroke or another cardiovascular pathology.<sup>20</sup> Increased cardiovascular risk in stroke survivors is largely due to metabolic abnormalities that are further exacerbated by physical inactivity.<sup>18</sup>



1  
2  
3  
4  
5  
6 While the American Stroke and Heart Associations recommend that stroke survivors engage  
7  
8 in regular aerobic exercise and PA to help prevent further stroke and lower cardiovascular  
9  
10 disease risk,<sup>19</sup> development of effective interventions is overdue. Many studies have  
11  
12 documented low PA<sup>21-28</sup> and high sedentary time following stroke.<sup>15, 21, 29</sup> Surprisingly, only  
13  
14 one small study (n=15) has tracked PA for greater than one year.<sup>27</sup> Longitudinal PA data  
15  
16 from participants, gathered using the same protocols and the same devices, could help us  
17  
18 understand how stroke survivors' PA and cardiovascular risk changes over time.<sup>30</sup>  
19  
20  
21 Understanding these associations and their interplay with depression and fatigue would  
22  
23 provide a stronger foundation on which to develop treatments that target improved PA in  
24  
25  
26  
27 this vulnerable group.  
28  
29  
30  
31  
32  
33  
34

### 35 **Aims & Hypotheses:**

36  
37  
38  
39 Primary aim: to describe the relationship between PA and cardiovascular risk factors over  
40  
41  
42 the 12 months following rehabilitation discharge after first ever stroke (baseline).  
43  
44  
45

46  
47 Secondary aim: to describe PA levels and their relationship to cardiovascular risk in the two  
48  
49 years following rehabilitation discharge.  
50  
51

52  
53 Tertiary aim: to explore the participant characteristics that are associated with PA (eg.  
54  
55  
56 MVPA duration, steps per day) and mobility (eg. walking ability, speed and endurance) at 12  
57  
58  
59  
60

1  
2  
3 and 24 months. Participant characteristics include demographics (eg. age, stroke severity),  
4  
5 mood and fatigue.  
6  
7

8  
9  
10 Primary hypothesis: at 12 months post discharge from rehabilitation low MVPA duration will  
11  
12 be associated with high systolic blood pressure.  
13  
14

15  
16  
17 Secondary hypothesis: a) there will be an association between PA measures (eg. MVPA  
18  
19 duration, sedentary time, energy expenditure, steps per day); and cardiovascular risk factors  
20  
21 (eg. systolic blood pressure, total cholesterol, smoking status) at baseline, 12 and 24 months  
22  
23 and b) activity levels will not approach levels recommended for cardiovascular risk reduction  
24  
25 at any time point.  
26  
27

28  
29  
30  
31  
32  
33 Tertiary hypothesis: better mobility will be associated with higher levels of PA. Further,  
34  
35 older stroke survivors who at baseline have poor mobility and high levels of fatigue and  
36  
37 depression are at risk of reduced PA at 12 and 24 months.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 METHODS

### 49 Design

50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Single centre, prospective longitudinal observational study, with participants assessed on  
4  
5 four occasions: baseline - discharge from outpatient physiotherapy (or inpatient discharge if  
6  
7 they don't receive follow-up physiotherapy) and at six, 12 and 24 months after discharge.  
8  
9

10 Recruitment commenced in October 2012 and is anticipated that 24 months follow-ups will  
11  
12 be completed by the end of 2017.  
13  
14

15  
16  
17  
18 This study is registered with the Australian New Zealand Clinical Trials Registry  
19  
20 (ACTRN12613000196741). Approval was granted from Alfred Hospital and La Trobe  
21  
22 University Research Ethics Committees.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 **Population**

34  
35  
36  
37  
38

39 Inclusion criteria are broad: all patients admitted to a large metropolitan rehabilitation  
40  
41 hospital (Caulfield Hospital, Melbourne) with first ever stroke, as defined by the World  
42  
43 Health Organisation, will be invited to participate. Exclusion criteria: previous stroke (TIA  
44  
45 allowed), concomitant diagnosis leading to palliative care, admitted for less than five days,  
46  
47 or living greater than two hours from Caulfield Hospital (to improve feasibility and reduce  
48  
49 drop outs).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Procedure**

Demographic details including age, gender, past medical history, type, location and initial severity of stroke (National Institutes of Health Stroke Scale), stroke and cardiovascular disease family history, living arrangements, social supports and employment will be collected at baseline.

Outcomes and assessment time points are in table 1. Baseline assessment will occur on completion of all physical rehabilitation, to ensure that physiotherapy (specifically encouragement from the physiotherapist and attendance at physiotherapy sessions) would not impact on PA levels.

## **Primary Outcome**

The primary outcome is duration of MVPA (average minutes/day) measured by the Sensewear MF Armband (SWAB). Moderate to vigorous PA is defined as >3 metabolic equivalent tasks (METs). Physical activity is a continuum, beginning with sedentary behaviour at <1.5METs to light PA (LPA) at 1.5 to 3 METs and up to MVPA at >3 METs. The SWAB measures the amount of time spent in these different activity levels. The SWAB is a triaxial accelerometer that uses multiple sensors to measure steps, motion, galvanic skin

1  
2  
3 response, skin temperature and heat flux. It is valid and reliable for measuring PA and  
4  
5 energy expenditure in people with chronic conditions including stroke<sup>31-34</sup> and reliably  
6  
7 measures steps in stroke.<sup>35</sup>  
8  
9

10  
11  
12  
13  
14 The SWAB will be worn for seven days, including at least one full weekend day, at each of  
15  
16 the four assessment points, and will be removed only for water-based activities. It will be  
17  
18 placed on the unaffected upper arm, which provides more accurate data due to blood flow  
19  
20 changes that occur in hemiplegic limbs.<sup>36</sup> Participants will be instructed to partake in their  
21  
22 normal activities, not more or less because they are wearing the armband. In line with best  
23  
24 practice, we will include PA data for those who have a minimum of 13 hours per day wear  
25  
26 time for a minimum of three days.<sup>37, 38</sup>  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 **Secondary Outcomes**

#### 39 **Physical Activity**

40  
41  
42  
43  
44 Other measures of PA measured by the SWAB will be collected as secondary outcomes:  
45  
46  
47  
48 sedentary time, LPA duration, number of MVPA and sedentary bouts ( $\geq 10$  minutes)<sup>9</sup> and  
49  
50 their duration, energy expenditure (kJ) and number of steps taken per day.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Physical Measurements of Cardiovascular Risk Factors

Systolic blood pressure, an important indicator of cardiovascular risk, is included in the most rigorous cardiovascular disease risk algorithms.<sup>39</sup> Blood pressure will be measured with a portable sphygmomanometer with the participant sitting for approximately 30 minutes prior (after the questionnaires and prior to the mobility assessments) and the average of two seated measurements will be used in accordance with guidelines proposed by the National Vascular Disease Prevention Alliance (NVDPA).<sup>40, 41</sup> Fasting lipid profile (TC, LDL-C, HDL-C, TC: HDL ratio and triglycerides) and plasma glucose samples will be obtained by a phlebotomist. Waist circumference will be measured, along with height and weight to calculate BMI.<sup>40, 41</sup>

## Mobility

To assess walking speed, balance, endurance and ability, the 10 metre walk test, timed up and go test, six minute walk test and Functional Ambulation Classification will be undertaken. These measures are considered valid and reliable in stroke survivors.<sup>42</sup> The six minute walk test will be measured on a 40m track. Participants will be instructed to cover as much distance as possible in the six minutes and will be informed as each minute elapses, with standardised phrases of encouragement.

### Further Stroke and Cardiovascular Events

At each follow-up assessment participants will be asked if they have had a TIA, stroke or other cardiovascular event, procedure or diagnosis since the previous assessment.

### Brief Questions Regarding Cardiovascular Risk Factors

Cigarette smoking, alcohol intake and diet will be established using the NVDPA standard guidelines.

### Questions Regarding Physical Activity

At each time point we will acquire information about PA undertaken in a regular week, its duration and frequency. At the baseline assessment we will use standard questions to acquire pre-morbid PA levels.

### **Mood, Fatigue and Cognition**

The Hospital Anxiety and Depression Scale (HADS)<sup>43</sup> and the Fatigue Severity Scale (FSS) will be administered. The FSS has been validated in stroke survivors.<sup>44</sup> The Montreal Cognitive Assessment, a brief valid cognitive screening tool in stroke,<sup>45</sup> will also be administered.

### **Disability**

The Self-Report Barthel Index, a valid and reliable measure of disability in stroke population<sup>46</sup> will be assessed.

### **Additional Physiotherapy**

Any further physiotherapy or activity based intervention since originally completing their therapy will be noted.

### **Sample Size Estimates**



1  
2  
3 We hypothesise an inverse relationship between MVPA duration and systolic blood pressure  
4  
5 at 12 months post baseline assessment. Evidence suggests that an increase in MVPA of 30  
6  
7 minutes/day over 12 months is associated with a 10mm Hg reduction in systolic blood  
8  
9 pressure.<sup>47</sup> Assuming that the standard deviation of the independent variable (MVPA) is 29  
10  
11 minutes/day<sup>32</sup> and the standard deviation of the dependent variable is 14.2mmHg,<sup>48</sup> then  
12  
13 70 subjects would be required for a probability of 80 percent that the study will detect a  
14  
15 relationship between the independent and the dependent variables at a two-sided 0.05  
16  
17 significance level, if the true change in the dependent variables is 0.167 units per unit  
18  
19 change in the independent variable.<sup>49</sup> Allowing for a 10% loss to follow-up over 12 months  
20  
21 the target sample size is 77.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 **Statistical Analyses**

34  
35  
36  
37 Primary Hypothesis: The relationship between MVPA duration and systolic blood pressure at  
38  
39 12 months will be examined using random effects regression modelling adjusted for  
40  
41 baseline MVPA duration with individual patients treated as random effects.  
42  
43  
44  
45  
46  
47

48 Secondary Hypothesis: a) The association between PA measures (eg. MVPA duration,  
49  
50 sedentary time, energy expenditure, steps per day); and cardiovascular risk factors (eg.  
51  
52 systolic blood pressure, total cholesterol, smoking status) at baseline, 12 and 24 months will  
53  
54 be examined using random effects regression modelling, with patients treated as random  
55  
56 effects to account for time. The PA and cardiovascular risk profile of participants at baseline,  
57  
58  
59  
60

1  
2  
3 12 and 24 months and the number of participants who have another stroke or  
4  
5 cardiovascular event or diagnosis will be reported descriptively.  
6  
7

8 b) The percentage of people achieving recommended activity levels to impact CV risk (30  
9  
10 minutes of MVPA per day) will be described.  
11  
12

13  
14  
15  
16 Tertiary Hypothesis: Once again, random effects modelling will be used to explore the  
17  
18 associations between participant characteristics (demographics, mood and fatigue), PA  
19  
20 levels and mobility at baseline to 12 and 24 months.  
21  
22  
23  
24  
25  
26  
27  
28  
29

## 30 DISCUSSION

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

36 Through tracking PA levels and cardiovascular risk factors for two years we will know more  
37  
38 about how these factors interact post stroke. By discovering this valuable information we  
39  
40 can target the stroke survivors most at risk and implement appropriate treatment,  
41  
42 preventative strategies and education.  
43  
44  
45  
46  
47  
48

49 Ultimately we hope to decrease the risk of further strokes and cardiovascular events in  
50  
51 stroke survivors. The cost of another event to this population is enormous: physically,  
52  
53 psychologically and emotionally, for the survivors themselves and to their families, carers  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and communities. Further cardiovascular events also have a significant financial cost to  
4  
5 increasingly overburdened health services.  
6  
7  
8  
9  
10

## 11 12 13 14 **SUMMARY AND CONCLUSIONS** 15

16  
17  
18  
19  
20  
21 This study will be the largest longitudinal PA dataset from stroke survivors to date. It will  
22  
23 help to identify factors present at discharge from physiotherapy that are associated with PA  
24  
25 levels and cardiovascular risk long after formal care ends. The findings of this study will be  
26  
27 the first step towards building effective interventions to improve PA in stroke survivors, with  
28  
29 the aim of improving long term health and quality of life for this vulnerable group.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Contributorship Statement:**

NF, JB and AE contributed to the study design, NF, JB and AE contributed to the statistical analysis plan, NF, JB and AE contributed to the acquisition of funds and NF, JB and AE contributed to the writing of the manuscript.

**Funding:**

The primary author is a recipient of a National Heart Foundation of Australia Postgraduate Scholarship (award no: PP 12M 6983). This work was supported by a Caulfield Hospital Major Research Grant, an Alfred Health Senior Physiotherapist Research Fellowship and an Australian Government Research Training Program Scholarship. The funders of this project had no role in the study design, writing of this protocol or decision to submit this manuscript for publication.

**Competing Interests:**

Ms. Fini reports grants from National Heart Foundation of Australia and grants from Caulfield Hospital, Alfred Health during the conduct of the study. Professor Bernhardt reports grants from National Health and Medical Research Council (Australia) during the conduct of the study and personal fees from Acting as a Scientific Advisor for DART Pharmaceuticals outside the submitted work. Professor Holland reports grants from Caulfield Hospital, Alfred Health during the conduct of the study.

**Acknowledgements:**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The authors would like to thank Professor Leonid Churilov for assistance with statistical analysis planning. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.

For peer review only

## REFERENCES

1. Australian Institute of Health and Welfare 2014. Australia's health 2014. Australia's health series no. 14. Cat. no. AUS 178. Canberra: AIHW. 2014.
2. Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. *Circulation*. 2011;124:2458-73.
3. Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, et al. Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association. *Circulation*. 2013;129:e28-e292.
4. Dunstan DW, Howard B, Healy GN, Owen N. Too much sitting - a health hazard. *Diabetes Res Clin Pract*. 2012;97:368-76.
5. Owen N, Sparling P, Healy G, Dunstan D, Matthews C. Sedentary Behaviour: Emerging Evidence for a New Health Risk. *Mayo Clin Proc*. 2010;85(12):1138-41.
6. Stamatakis E, Hamer M, Dunstan DW. Screen-Based Entertainment Time, All-Cause Mortality, and Cardiovascular Events. Population-Based Study With Ongoing Mortality and Hospital Events Follow-Up. *J Am Coll Cardiol*. 2011;57(3):292-9.
7. ACSM and AHA. Physical Activity and Public Health: Updated Recommendation for Adults From the American College of Sports Medicine and the American Heart Association. *Circulation*. 2007;116:1081-93.
8. Samitz G, Egger M, Zwahlen M. Domains of physical activity and all-cause mortality: systematic review and dose-response meta-analysis of cohort studies. *Int J Epidemiol*. 2011;40:1382-400.
9. Haskell W, Lee I, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical Activity and Public Health: Updated Recommendation for Adults from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc*. 2007;39:1423-34.
10. Australia's Physical Activity and Sedentary Behaviour Guidelines In: Australian Government DoH, editor. 2014.
11. Decreasing Sedentary Behavior and Physical Inactivity by Moving More and Sitting Less. In: Services USDoHaH, editor. 2013.
12. Biddle S, Cavill N, Ekelund U, Gorely T, Griffiths M, Jago R, et al. Sedentary Behaviour and Obesity: Review of the Current Scientific Evidence. In: Health Do, Department for Children SaF, editors. 2010.
13. Thrift AG, Thayabaranathan T, Howard G, Howard VJ, Rothwell PM, Feigin VL, et al. Global Stroke Statistics. *Int J Stroke*. 2016;0(0):1-20.
14. Senes S. AIHW: How we Manage Stroke in Australia. AIHW cat. no. CVD 31. Canberra: Australian Institute of Health and Welfare. . 2006.
15. English C, Healy GN, Coates A, Lewis L, Olds T, Bernhardt J. Sitting and Activity Time in People With Stroke. *Phys Ther*. 2016;96(2):193-201 9p.
16. Hackett M, Yapa C, Parag V, Anderson C. Frequency of depression after stroke: a systematic review of observational studies. *Stroke*. 2005;36:1330-40.
17. Duncan F, Wu S, Mead GE. Frequency and natural history of fatigue after stroke: a systematic review of longitudinal studies. *J Psychosom Res*. 2012;73:18-27.
18. Ivey FM, Hafer-Macko CE, Macko RF. Exercise Training for Cardiometabolic Training After Stroke *J Cardiopulm Rehabil Prev*. 2008;28:2-11.
19. Billinger SA, Arena R, Bernhardt J, Eng JJF, Barry A. , Johnson CM, MacKay-Lyons M, et al. Physical Activity and Exercise Recommendations for Stroke Survivors: A Statement for Healthcare

- 1  
2  
3 Professionals From the American Heart Association/American Stroke Association. *Stroke*.  
4 2014;45:2532-53.
- 5 20. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-Year Survival After First-  
6 Ever Stroke in the Perth Community Stroke Study. *Stroke*. 2003;34:1842-6.
- 7 21. Moore SA, Hallsworth K, Plotz T, Ford GA, Rochester L, Trenell MI. Physical activity,  
8 sedentary behaviour and metabolic control following stroke: a cross-sectional and longitudinal  
9 study. *PLoS One*. 2013;8(1):e55263.
- 10 22. Michael K, Goldberg AP, Treuth MS, Beans J, Normandt P, Macko RF. Progressive adaptive  
11 physical activity in stroke improves balance, gait, and fitness: preliminary results. *Top Stroke Rehabil*.  
12 2009;16(2):133-9.
- 13 23. Mudge S, Stott NS. Timed walking tests correlate with daily step activity in persons with  
14 stroke. *Arch Phys Med Rehabil*. 2009;90(2):296-301.
- 15 24. Shaughnessy M, Michael KM, Sorkin JD, Macko RF. Steps after stroke: capturing ambulatory  
16 recovery. *Stroke; a journal of cerebral circulation*. 2005;36(6):1305-7.
- 17 25. Bernhardt J, Dewey H, Thrift A, Donnan G. Inactive and Alone: Physical Activity within the  
18 First 14 Days of Acute Stroke Unit Care. *Stroke*. 2004;35(4):1005-9.
- 19 26. van de Port IG, Valkenet K, Schuurmans M, Visser-Meily JM. How to increase activity level in  
20 the acute phase after stroke. *J Clin Nurs*. 2012;21(23-24):3574-8.
- 21 27. Kunkel D, Fitton C, Burnett M, Ashburn A. Physical inactivity post-stroke: a 3-year  
22 longitudinal study. *Disabil Rehabil*. 2015;37(4):304-10.
- 23 28. Rand D, Eng JJ, Tang PF, Jeng JS, Hung C. How active are people with stroke?: use of  
24 accelerometers to assess physical activity. *Stroke; a journal of cerebral circulation*. 2009;40(1):163-8.
- 25 29. Tiegies Z, Mead GE, Allerhand M, Duncan F, van Wijck F, Fitzsimons C, et al. Sedentary  
26 Behavior in the First Year After Stroke: A Longitudinal Cohort Study With Objective Measures. *Arch*  
27 *Phys Med Rehabil*. 2015;96:15-23.
- 28 30. Fini NA, Holland AE, Keating J, Simek J, Bernhardt J. How physically active are people  
29 following stroke? Systematic review and quantitative synthesis. *Phys Ther*. 2017;97(Early Online):1-  
30 11.
- 31 31. Cereda C, Pezzoli G, Barichella M. Role of an Electronic Armband in Motor Function  
32 Monitoring in Patient's with Parkinson's Disease. *Nutrition*. 2010;26:240-2.
- 33 32. Troosters T, Sciruba F, Battaglia S, Langer D, Valluri S, Martino L, et al. Physical Inactivity in  
34 Patients with COPD, a Controlled Multi-Center Pilot Study. *Respir Med*. 2010;104:1005-11.
- 35 33. Camillo C, Pitta F, Possani H, Barbosa M, Marques D, Cavalheri V, et al. Heart Rate Variability  
36 and Disease Characteristics in Patients with COPD. *Lung*. 2008;186:393-401.
- 37 34. Moore SA, Hallsworth K, Bluck LJ, Ford GA, Rochester L, Trenell MI. Measuring energy  
38 expenditure after stroke: validation of a portable device. *Stroke; a journal of cerebral circulation*.  
39 2012;43(6):1660-2.
- 40 35. Vanroy C, Vissers D, Cras P, Beyne S, Feys H, Vanlandewijck Y, et al. Physical activity  
41 monitoring in stroke: SenseWear Pro2 Activity accelerometer versus Yamax Digi-Walker SW-200  
42 Pedometer. *Disabil Rehabil*. 2014;36(20):1695-703.
- 43 36. Wanklyn P, Ilsley DW, Greenstein D, Hampton IFG, Roper TA, Kester RC, et al. The cold  
44 hemiplegic arm. *Stroke*. 1994;25(9):1765-70.
- 45 37. Herrmann SD, Barreira TV, Kang M, Ainsworth BE. How Many Hours are Enough?  
46 Accelerometer Wear Time May Provide Bias in Daily Activity Estimates. *Journal of Physical Activity and*  
47 *Health*. 2013;10:742-9.
- 48 38. Mudge S, Stott NS. Test-retest reliability of the StepWatch Activity Monitor outputs in  
49 individuals with chronic stroke. *Clin Rehabil*. 2008;22(10-11):871-7.
- 50 39. Damen JAAG, Hooft L, Schuit E, Debray TPA, Collins GS, Tzoulaki I, et al. Prediction models  
51 for cardiovascular disease risk in the general population: systematic review. *BMJ*.  
52 2016;353(i2416):11 pages.
- 53  
54  
55  
56  
57  
58  
59  
60

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
40. National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk. 2009.
41. National Vascular Disease Prevention Alliance. Guidelines for management of absolute cardiovascular disease risk. 2012.
42. Hill K, Denisenko S, Miller K, Clements T, Batchelor F. Clinical outcome measurement in adult neurological physiotherapy 3rd ed. Melbourne: Australian Physiotherapy Association; 2005.
43. O'Rourke S, MacHale S, Signorini D, Dennis M. Detecting psychiatric morbidity after stroke: comparison of the GHQ and the HAD Scale. *Stroke*. 1998;29(5):980-5.
44. Tseng BY, Billinger SA, Gajewski BJ, Kluding PM. Exertion Fatigue and Chronic Fatigue are Two Distinct Constructs in People post Stroke. . *Stroke*. 2010;41:2908-12.
45. Chiti G, Pantoni L. Use of Montreal Cognitive Assessment in Patients with Stroke. *Stroke*. 2014;45:3135-40.
46. Collin C, Wade DT, Davies S, Horne V. The Barthel Index: A Reliability Study. *Int Disabil Stud*. 1988;10(2):61-3.
47. Rimmer JH, Rauworth AE, Wang EC, Nicola TL, Hill B. A Preliminary Study to Examine the Effects of Aerobic and Therapeutic (Nonaerobic) Exercise on Cardiorespiratory Fitness and Coronary Risk Reduction in Stroke Survivors. *Arch Phys Med Rehabil*. 2009;90:407-12.
48. Jorgenson JR, Bech-Pederson DT, Zeeman P, Sorenson J. Effect of Intensive Outpatient Physical Training on Gait Performance & CV Health in People with Hemiparesis After Stroke. . *Phys Ther*. 2010;90(4):527-38.
49. Schoenfeld DA. Statistical considerations for clinical trials and scientific experiments Massachusetts: The Massachusetts General Hospital's Biostatistics Center; [cited 2011 05].



Protocol for a Longitudinal Study into Physical Activity and Cardiovascular Risk in People with Stroke: Tables

Table 1: Assessment Time-points & Outcomes

Outcomes Measured	Baseline	6 months	12 months	24 months
Demographics	✓			
MVPA Duration	✓	✓	✓	✓
Other PA Outcomes	✓	✓	✓	✓
Fasting Lipid Profile & Plasma Glucose	✓		✓	✓
Blood Pressure, Waist Circumference & BMI	✓	✓	✓	✓
Mobility Measures	✓	✓	✓	✓
Questions Regarding Further Stroke and Cardiovascular Events		✓	✓	✓
Questions Regarding Cardiovascular Risk Factors & PA	✓	✓	✓	✓
HADS, FSS & MOCA	✓	✓	✓	✓
Self-Report Barthel Index	✓	✓	✓	✓

MVPA = moderate to vigorous physical activity; PA = physical activity; BMI = body mass index; HADS = hospital anxiety and depression scale; FSS = fatigue severity scale; MOCA = Montreal cognitive assessment

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	N/A Protocol
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5-6
<b>Methods</b>			<b>7</b>
Study design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-12
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-12
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	12-13
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	13-14
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	13-14
		(b) Describe any methods used to examine subgroups and interactions	13-14
		(c) Explain how missing data were addressed	N/A
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	N/A

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			N/A Protocol
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			N/A Protocol
Key results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## What is the relationship between Physical Activity and Cardiovascular Risk Factors in Stroke Survivors Post Completion of Rehabilitation? Protocol for a Longitudinal Study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019193.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Oct-2017
Complete List of Authors:	Fini, Natalie; University of Melbourne, School of Health Sciences , Physiotherapy; Alfred Health, Physiotherapy Bernhardt, Julie; Florey Institute of Neuroscience and Mental Health - Austin Campus, Stroke Division Holland, Anne E.; Alfred Health, Physiotherapy; La Trobe University, Physiotherapy
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Cardiovascular medicine, Rehabilitation medicine
Keywords:	Stroke < NEUROLOGY, physical activity, cardiovascular risk, longitudinal

SCHOLARONE™  
Manuscripts

1  
2  
3 Title:  
4  
5

6 **What is the relationship between Physical Activity and Cardiovascular Risk Factors in**  
7  
8 **Stroke Survivors Post Completion of Rehabilitation? Protocol for a Longitudinal Study.**  
9

10  
11  
12  
13  
14  
15 Authors:  
16

17  
18 **Natalie A. Fini**<sup>1,2,3</sup>; Julie Bernhardt<sup>4</sup>; Anne E. Holland<sup>2,5</sup>  
19

20  
21 Affiliations:  
22

23 <sup>1</sup> Physiotherapy Department, Caulfield Hospital, Alfred Health  
24

25 <sup>2</sup> Physiotherapy Department, School of Allied Health, La Trobe University  
26

27 <sup>3</sup> Physiotherapy Department, Melbourne School of Health Sciences, The University of  
28 Melbourne  
29

30 <sup>4</sup> Stroke Division, Florey Institute of Neurosciences and Mental Health, The University of  
31 Melbourne  
32

33 <sup>5</sup> Physiotherapy Department, Alfred Health  
34  
35  
36

37 Contact Information:  
38

39 *Corresponding Author:*  
40

41 Natalie A. Fini  
42

43 Physiotherapy Department, Melbourne School of Health Sciences  
44

45 Level 7, 161 Barry St  
46

47 Alan Gilbert Building  
48

49 The University of Melbourne  
50

51 Parkville VIC 3010  
52

53 Australia  
54

55 Ph: +61 401 303 749; Fax: +61 3 8344 4188  
56

57 Email: [natalie.fini@unimelb.edu.au](mailto:natalie.fini@unimelb.edu.au)  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9 Julie Bernhardt

10 Florey Institute of Neurosciences and Mental Health, The University of Melbourne

11 Heidelberg

12 Australia

13  
14  
15  
16  
17  
18  
19 Anne E. Holland

20 La Trobe University / Alfred Health

21 Melbourne

22 Australia

23  
24  
25  
26  
27  
28  
29 Key Words:

30 stroke, physical activity; cardiovascular risk, longitudinal

31  
32  
33  
34  
35  
36  
37  
38 Word Count:

39 2428 words including abstract

**ABSTRACT****Introduction:**

Physical activity (PA) can modify cardiovascular and other health risks in people with stroke, but we know little about long term PA in this group. This study aims to describe PA levels and investigate relationships between PA, cardiovascular risk factors, mobility and participant characteristics (eg. age, mood and fatigue) in the two years following rehabilitation discharge after first stroke.

**Methods and Analysis**

This is a longitudinal observational study with follow up at six, 12, and 24 months after rehabilitation discharge. Inclusion criteria are broad; excluding only those with previous stroke, palliative diagnosis, living more than two hours from the centre or admitted less than five days.

The primary outcome of interest is duration of moderate-vigorous PA (minutes/day) measured by the Sensewear MF Armband (SWAB). Secondary outcomes include other PA measures measured with the SWAB; cardiovascular risk factors (eg. systolic blood pressure, fasting lipid profile, smoking status), mobility (10 metre walk test), the Hospital Anxiety and Depression Scale and the Fatigue Severity Scale. All outcomes, except blood tests are gathered at each time point.

1  
2  
3 The target sample size is 77. We will explore associations between PA levels, cardiovascular  
4 risk factors, mobility and participant characteristics at baseline compared to six, 12 and 24  
5 months using random effects regression modelling.  
6  
7  
8  
9

10  
11  
12 The long term PA of stroke survivors is largely unknown. We hope to identify factors that  
13 influence PA and cardiovascular risk in this population, which may help health professionals  
14 target the stroke survivors most at risk and implement appropriate treatment, preventative  
15 strategies and education.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **Ethics and Dissemination**

27  
28  
29 Approval was granted from Alfred Hospital and La Trobe University Research Ethics  
30 Committees. The study results will be disseminated in a number of ways including journal  
31 publication and international conference presentations. This study is registered with the  
32 Australian New Zealand Clinical Trials Registry (ACTRN12613000196741).  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### **Strengths and Limitations of this Study:**

#### **Strengths:**

- This study will be the largest longitudinal PA dataset from stroke survivors to date.
- Investigates the important issues of secondary prevention and cardiovascular risk after stroke.
- Measures a number of PA outcomes objectively using a device that has been validated in stroke survivors.

#### **Limitations:**

- It is a relatively small, single centre study.
- Does not measure PA in the acute phase after stroke.
- The follow-up time points are measured from rehabilitation discharge rather than stroke onset as has recently been recommended by the Stroke Recovery and Rehabilitation Roundtable Taskforce.

## INTRODUCTION AND RATIONALE

The importance of physical activity (PA) for cardiovascular health is well documented<sup>1-3</sup> and the detrimental effects of sedentary behaviour are substantial.<sup>4-6</sup> Physical activity guidelines for healthy individuals state that 30 minutes of moderate to vigorous intensity PA (MVPA) should be undertaken five days per week.<sup>7</sup> Adherence to these guidelines is associated with a 14% relative risk reduction in all-cause mortality.<sup>8</sup> To achieve cardiovascular benefits, it is recommended that MVPA be accumulated in bouts of at least 10 minutes.<sup>9</sup> Long bouts of uninterrupted sitting are associated with an increased rate of cardiovascular and all-cause mortality in healthy populations.<sup>5,6</sup> Recommendations about breaking up sitting time have been highlighted in government documents and recommendations internationally.<sup>10-12</sup> Increasing PA and reducing sedentary behaviour are now global targets for better health in a wide range of populations.

Stroke is a major cause of disability worldwide.<sup>13</sup> Mobility limitations are common following a stroke<sup>14</sup> and are associated with poor participation in PA and higher levels of sedentary behaviour than community-dwelling older adults.<sup>15</sup> Depression and fatigue, common in stroke, are also associated with lower PA.<sup>16,17</sup> Almost one third of stroke patients will suffer another stroke within five years<sup>18,19</sup> and 50% of people who survive 5-10 years will die of recurrent stroke or another cardiovascular pathology.<sup>20</sup> Increased cardiovascular risk in stroke survivors is largely due to metabolic abnormalities that are further exacerbated by physical inactivity.<sup>20</sup>

1  
2  
3  
4  
5  
6 While the American Stroke and Heart Associations recommend that stroke survivors engage  
7  
8 in regular aerobic exercise and PA to help prevent further stroke and lower cardiovascular  
9  
10 disease risk,<sup>19</sup> development of effective interventions is overdue. Many studies have  
11  
12 documented low PA<sup>21-28</sup> and high sedentary time following stroke.<sup>15, 21, 29</sup> Surprisingly, only  
13  
14 one small study (n=15) has tracked PA for greater than one year.<sup>27</sup> Longitudinal PA data  
15  
16 from participants, gathered using the same protocols and the same devices, could help us  
17  
18 understand how stroke survivors' PA and cardiovascular risk changes over time.<sup>30</sup>  
19  
20  
21 Understanding these associations and their interplay with depression and fatigue would  
22  
23 provide a stronger foundation on which to develop treatments that target improved PA in  
24  
25 this vulnerable group.  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Aims & Hypotheses:**

#### 36 37 38 **Overarching Aim**

39  
40 To describe PA levels and their relationship to cardiovascular risk factors over the two years  
41  
42 following discharge from rehabilitation after first ever stroke.  
43  
44  
45  
46  
47  
48  
49  
50

#### 51 **Specific Aim 1:**

52  
53 To document PA levels at rehabilitation discharge (baseline), six, 12 and 24 months later.  
54  
55  
56  
57  
58  
59  
60

**Specific Aim 2:**

To document the relationship between PA levels and cardiovascular risk factors at rehabilitation discharge (baseline), and six, 12 and 24 months later.

**Specific Aim 3:**

To explore the participant characteristics that are associated with PA (eg. MVPA duration, steps per day) and mobility (eg. walking ability, speed and endurance) at 12 and 24 months. Participant characteristics include demographics (eg. age, stroke severity), mood and fatigue.

**Specific Hypothesis 1:**

Physical activity levels will not approach levels recommended for cardiovascular risk factor reduction at any time point.

**Specific Hypothesis 2:**

- a) There will be an association between PA measures (eg. MVPA duration, sedentary time, energy expenditure, steps per day); and cardiovascular risk factors (eg. systolic blood pressure, total cholesterol, smoking status) at baseline, six, 12 and 24 months.
- b) At 12 months post discharge from rehabilitation low MVPA duration will be associated with higher systolic blood pressure.

**Specific Hypothesis 3:**

- a) Better mobility will be associated with higher levels of PA.
- b) Further, older stroke survivors who at baseline have poor mobility and high levels of fatigue and depression are at risk of a reduction in PA at 12 and 24 months post rehabilitation discharge.

**METHODS****Design**

Single centre, prospective longitudinal observational study, with participants assessed on four occasions: baseline - discharge from outpatient physiotherapy (or inpatient discharge if they don't receive follow-up physiotherapy) and at six, 12 and 24 months after discharge. Recruitment commenced in October 2012 and is anticipated that the 24 month follow-ups will be completed by the end of 2017.

## **Population**

Inclusion criteria are broad: all patients admitted to a large metropolitan rehabilitation hospital (Caulfield Hospital, Melbourne) with first ever stroke, as defined by the World Health Organisation, will be invited to participate. Exclusion criteria: previous stroke (TIA allowed), concomitant diagnosis leading to palliative care, admitted for less than five days, or living greater than two hours from Caulfield Hospital (to improve feasibility and reduce drop outs).

## **Procedure**

Demographic details including age, gender, past medical history, type, location and initial severity of stroke (National Institutes of Health Stroke Scale), stroke and cardiovascular disease family history, living arrangements, social supports and employment will be collected at baseline.

Outcomes and assessment time points are in table 1. Baseline assessment will occur on completion of all physical rehabilitation, to ensure that physiotherapy (specifically

1  
2  
3 encouragement from the physiotherapist and attendance at physiotherapy sessions) would  
4  
5 not impact on PA levels.  
6  
7  
8  
9  
10

### 11 **Primary Outcome**

12  
13  
14  
15  
16  
17  
18  
19  
20  
21 The primary outcome is duration of MVPA (average minutes/day) measured by the  
22  
23 Sensewear MF Armband (SWAB). Moderate to vigorous PA is defined as >3 metabolic  
24  
25 equivalent tasks (METs). Physical activity is a continuum, beginning with sedentary  
26  
27 behaviour at <1.5METs to light PA (LPA) at 1.5 to 3 METs and up to MVPA at >3 METs. The  
28  
29 SWAB measures the amount of time spent in these different activity levels. The SWAB is a  
30  
31 triaxial accelerometer that uses multiple sensors to measure steps, motion, galvanic skin  
32  
33 response, skin temperature and heat flux. It is valid and reliable for measuring PA and  
34  
35 energy expenditure in people with chronic conditions including stroke<sup>31-34</sup> and reliably  
36  
37 measures steps in stroke.<sup>35</sup>  
38  
39  
40  
41  
42  
43  
44  
45

46 The SWAB will be worn for seven days, including at least one full weekend day, at each of  
47  
48 the four assessment points, and will be removed only for water-based activities. It will be  
49  
50 placed on the unaffected upper arm, which provides more accurate data due to blood flow  
51  
52 changes that occur in hemiplegic limbs.<sup>36</sup> Participants will be instructed to partake in their  
53  
54 normal activities, not more or less because they are wearing the armband. In line with best  
55  
56  
57  
58  
59  
60

1  
2  
3 practice, we will include PA data for those who have a minimum of 13 hours per day wear  
4  
5 time for a minimum of three days.<sup>37,38</sup>  
6  
7  
8  
9  
10

## 11 **Secondary Outcomes**

### 12 **Physical Activity**

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 Other measures of PA measured by the SWAB will be collected as secondary outcomes:  
29  
30 sedentary time, LPA duration, number of MVPA and sedentary bouts ( $\geq 10$  minutes)<sup>9</sup> and  
31  
32 their duration, energy expenditure (kJ) and number of steps taken per day.  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Physical Measurements of Cardiovascular Risk Factors**

43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000



1  
2  
3 National Vascular Disease Prevention Alliance (NVDPA).<sup>40,41</sup> Fasting lipid profile (TC, LDL-C,  
4  
5 HDL-C, TC: HDL ratio and triglycerides) and plasma glucose samples will be obtained by a  
6  
7 phlebotomist. Waist circumference will be measured, along with height and weight to  
8  
9 calculate BMI.<sup>40,41</sup>  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Mobility**

21 To assess walking speed, balance, endurance and ability, the 10 metre walk test, timed up  
22  
23 and go test, six minute walk test and Functional Ambulation Classification will be  
24  
25 undertaken. These measures are considered valid and reliable in stroke survivors.<sup>42</sup> The six  
26  
27 minute walk test will be measured on a 40m track. Participants will be instructed to cover as  
28  
29 much distance as possible in the six minutes and will be informed as each minute elapses,  
30  
31 with standardised phrases of encouragement.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Further Stroke and Cardiovascular Events**

44  
45  
46  
47  
48  
49 At each follow-up assessment participants will be asked if they have had a TIA, stroke or  
50  
51 other cardiovascular event, procedure or diagnosis since the previous assessment.  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Brief Questions Regarding Cardiovascular Risk Factors

Cigarette smoking, alcohol intake and diet will be established using the NVDPA standard guidelines.<sup>40,41</sup> The following questions will be asked: Have you ever smoked? If so, are you still a smoker? If not, how long ago did you stop? How many packs did you smoke per day and for how many years? Do you have more than 2 standard alcoholic drinks per day? Do you maintain a diet high in fruit and vegetables and low in fat, sugar and salt?

### Questions Regarding Physical Activity

At each time point we will acquire information about PA undertaken in a regular week, its duration and frequency. Specific questions include: "Do you participate in regular PA? If so, what activities do you do? How often do you do them in a regular week? How long do you do them for each time? At the baseline assessment we will use the same standard questions to acquire pre-morbid PA levels.

### Mood, Fatigue and Cognition

1  
2  
3 The Hospital Anxiety and Depression Scale (HADS)<sup>43</sup> and the Fatigue Severity Scale (FSS) will  
4  
5 be administered. The FSS has been validated in stroke survivors.<sup>44</sup> The Montreal Cognitive  
6  
7 Assessment, a brief valid cognitive screening tool in stroke,<sup>45</sup> will also be administered.  
8  
9

## 10 11 12 13 14 15 16 17 **Disability**

18  
19  
20  
21  
22 The Self-Report Barthel Index, a valid and reliable measure of disability in stroke  
23  
24 population<sup>46</sup> will be assessed.  
25  
26  
27  
28  
29  
30  
31  
32  
33

## 34 35 **Additional Physiotherapy**

36  
37  
38  
39  
40  
41 Any further physiotherapy or activity based intervention since originally completing their  
42  
43 therapy will be noted.  
44  
45  
46  
47  
48  
49  
50

## 51 52 53 54 **Sample Size Estimates**

55 We hypothesise an inverse relationship between MVPA duration and systolic blood pressure  
56  
57 at 12 months post baseline assessment. Evidence suggests that an increase in MVPA of 30  
58  
59  
60

minutes/day over 12 months is associated with a 10mm Hg reduction in systolic blood pressure.<sup>47</sup> Assuming that the standard deviation of the independent variable (MVPA) is 29 minutes/day<sup>32</sup> and the standard deviation of the dependent variable is 14.2mmHg,<sup>48</sup> then 70 subjects would be required for a probability of 80 percent that the study will detect a relationship between the independent and the dependent variables at a two-sided 0.05 significance level, if the true change in the dependent variables is 0.167 units per unit change in the independent variable.<sup>49</sup> Allowing for a 10% loss to follow-up over 12 months the target sample size is 77.

### **Statistical Analyses**

#### Specific Aim 1:

The PA and cardiovascular risk profile of participants at baseline, six, 12 and 24 months and the number of participants who have another stroke or cardiovascular event or diagnosis will be reported descriptively. The percentage of people achieving recommended activity levels to influence cardiovascular risk (30 minutes of MVPA per day) will be described.

#### Specific Aim 2:

- a) The association between PA measures (eg. MVPA duration, sedentary time, energy expenditure, steps per day); and cardiovascular risk factors (eg. systolic blood pressure, total cholesterol, smoking status) at baseline, six, 12 and 24 months will be

1  
2  
3 examined using random effects regression modeling, with patients treated as  
4  
5 random effects to account for time.  
6  
7

- 8  
9 b) The relationship between MVPA duration and systolic blood pressure at 12 months  
10  
11 will be examined using random effects regression modelling adjusted for baseline  
12  
13 MVPA duration with individual patients treated as random effects.  
14  
15

16  
17  
18  
19 Specific Aim 3:

20  
21 Once again, random effects modelling will be used to explore the associations between  
22  
23 participant characteristics (demographics, mood and fatigue), PA levels and mobility at 12  
24  
25 and 24 months relative to baseline.  
26  
27  
28  
29  
30  
31  
32

### 33 **Ethics and Dissemination:**

34  
35 Approval was granted from Alfred Hospital and La Trobe University Research Ethics  
36  
37 Committees. The study results will be disseminated in a number of ways including journal  
38  
39 publication and international conference presentations. This study is registered with the  
40  
41 Australian New Zealand Clinical Trials Registry (ACTRN12613000196741).  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 **DISCUSSION**

53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This study will be the largest longitudinal PA dataset from stroke survivors to date. Through  
4  
5 tracking PA levels and cardiovascular risk factors for two years we will know more about  
6  
7 how these factors interact post stroke. This study will help to identify factors present at  
8  
9 discharge from physiotherapy that are associated with low PA levels and increased  
10  
11 cardiovascular risk long after formal care ends. By discovering this valuable information we  
12  
13 can target the stroke survivors most at risk and implement appropriate treatment,  
14  
15 preventative strategies and education prior to discharge from therapy. The ultimate aim is  
16  
17 for health professionals to employ behaviour change strategies to facilitate life-long stroke  
18  
19 survivor participation in PA. The findings of this study will be the first step towards building  
20  
21 effective interventions to improve PA in stroke survivors, with the aim of improving long  
22  
23 term health and quality of life for this vulnerable group.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Contributorship Statement:**

NF, JB and AE contributed to the study design, NF, JB and AE contributed to the statistical analysis plan, NF, JB and AE contributed to the acquisition of funds and NF, JB and AE contributed to the writing of the manuscript.

**Funding:**

The primary author is a recipient of a National Heart Foundation of Australia Postgraduate Scholarship (award no: PP 12M 6983). This work was supported by a Caulfield Hospital Major Research Grant, an Alfred Health Senior Physiotherapist Research Fellowship and an Australian Government Research Training Program Scholarship. The funders of this project had no role in the study design, writing of this protocol or decision to submit this manuscript for publication.

**Competing Interests:**

Ms. Fini reports grants from National Heart Foundation of Australia and grants from Caulfield Hospital, Alfred Health during the conduct of the study. Professor Bernhardt reports grants from National Health and Medical Research Council (Australia) during the conduct of the study and personal fees from Acting as a Scientific Advisor for DART Pharmaceuticals outside the submitted work. Professor Holland reports grants from Caulfield Hospital, Alfred Health during the conduct of the study.

**Acknowledgements:**

1  
2  
3 The authors would like to thank Professor Leonid Churilov for assistance with statistical analysis  
4  
5 planning. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support  
6  
7 from the Victorian Government and in particular the funding from the Operational Infrastructure  
8  
9 Support Grant.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## REFERENCES

1. Australian Institute of Health and Welfare 2014. Australia's health 2014. Australia's health series no. 14. Cat. no. AUS 178. Canberra: AIHW. 2014.
2. Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. *Circulation*. 2011;124:2458-73.
3. Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, et al. Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association. *Circulation*. 2013;129:e28-e292.
4. Dunstan DW, Howard B, Healy GN, Owen N. Too much sitting - a health hazard. *Diabetes Res Clin Pract*. 2012;97:368-76.
5. Owen N, Sparling P, Healy G, Dunstan D, Matthews C. Sedentary Behaviour: Emerging Evidence for a New Health Risk. *Mayo Clin Proc*. 2010;85(12):1138-41.
6. Stamatakis E, Hamer M, Dunstan DW. Screen-Based Entertainment Time, All-Cause Mortality, and Cardiovascular Events. Population-Based Study With Ongoing Mortality and Hospital Events Follow-Up. *J Am Coll Cardiol*. 2011;57(3):292-9.
7. ACSM and AHA. Physical Activity and Public Health: Updated Recommendation for Adults From the American College of Sports Medicine and the American Heart Association. *Circulation*. 2007;116:1081-93.
8. Samitz G, Egger M, Zwahlen M. Domains of physical activity and all-cause mortality: systematic review and dose-response meta-analysis of cohort studies. *Int J Epidemiol*. 2011;40:1382-400.
9. Haskell W, Lee I, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical Activity and Public Health: Updated Recommendation for Adults from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc*. 2007;39:1423-34.
10. Australia's Physical Activity and Sedentary Behaviour Guidelines In: Australian Government DoH, editor. 2014.
11. Decreasing Sedentary Behavior and Physical Inactivity by Moving More and Sitting Less. In: Services USDoHaH, editor. 2013.
12. Biddle S, Cavill N, Ekelund U, Gorely T, Griffiths M, Jago R, et al. Sedentary Behaviour and Obesity: Review of the Current Scientific Evidence. In: Health Do, Department for Children SaF, editors. 2010.
13. Thrift AG, Thayabaranathan T, Howard G, Howard VJ, Rothwell PM, Feigin VL, et al. Global Stroke Statistics. *Int J Stroke*. 2016;0(0):1-20.
14. Senes S. AIHW: How we Manage Stroke in Australia. AIHW cat. no. CVD 31. Canberra: Australian Institute of Health and Welfare. . 2006.
15. English C, Healy GN, Coates A, Lewis L, Olds T, Bernhardt J. Sitting and Activity Time in People With Stroke. *Phys Ther*. 2016;96(2):193-201 9p.
16. Hackett M, Yapa C, Parag V, Anderson C. Frequency of depression after stroke: a systematic review of observational studies. *Stroke*. 2005;36:1330-40.
17. Duncan F, Wu S, Mead GE. Frequency and natural history of fatigue after stroke: a systematic review of longitudinal studies. *J Psychosom Res*. 2012;73:18-27.
18. Ivey FM, Hafer-Macko CE, Macko RF. Exercise Training for Cardiometabolic Training After Stroke *J Cardiopulm Rehabil Prev*. 2008;28:2-11.
19. Billinger SA, Arena R, Bernhardt J, Eng JJF, Barry A. , Johnson CM, MacKay-Lyons M, et al. Physical Activity and Exercise Recommendations for Stroke Survivors: A Statement for Healthcare

- 1  
2  
3 Professionals From the American Heart Association/American Stroke Association. *Stroke*.  
4 2014;45:2532-53.
- 5 20. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-Year Survival After First-  
6 Ever Stroke in the Perth Community Stroke Study. *Stroke*. 2003;34:1842-6.
- 7 21. Moore SA, Hallsworth K, Plotz T, Ford GA, Rochester L, Trenell MI. Physical activity,  
8 sedentary behaviour and metabolic control following stroke: a cross-sectional and longitudinal  
9 study. *PLoS One*. 2013;8(1):e55263.
- 10 22. Michael K, Goldberg AP, Treuth MS, Beans J, Normandt P, Macko RF. Progressive adaptive  
11 physical activity in stroke improves balance, gait, and fitness: preliminary results. *Top Stroke Rehabil*.  
12 2009;16(2):133-9.
- 13 23. Mudge S, Stott NS. Timed walking tests correlate with daily step activity in persons with  
14 stroke. *Arch Phys Med Rehabil*. 2009;90(2):296-301.
- 15 24. Shaughnessy M, Michael KM, Sorkin JD, Macko RF. Steps after stroke: capturing ambulatory  
16 recovery. *Stroke; a journal of cerebral circulation*. 2005;36(6):1305-7.
- 17 25. Bernhardt J, Dewey H, Thrift A, Donnan G. Inactive and Alone: Physical Activity within the  
18 First 14 Days of Acute Stroke Unit Care. *Stroke*. 2004;35(4):1005-9.
- 19 26. van de Port IG, Valkenet K, Schuurmans M, Visser-Meily JM. How to increase activity level in  
20 the acute phase after stroke. *J Clin Nurs*. 2012;21(23-24):3574-8.
- 21 27. Kunkel D, Fitton C, Burnett M, Ashburn A. Physical inactivity post-stroke: a 3-year  
22 longitudinal study. *Disabil Rehabil*. 2015;37(4):304-10.
- 23 28. Rand D, Eng JJ, Tang PF, Jeng JS, Hung C. How active are people with stroke?: use of  
24 accelerometers to assess physical activity. *Stroke; a journal of cerebral circulation*. 2009;40(1):163-8.
- 25 29. Tiegies Z, Mead GE, Allerhand M, Duncan F, van Wijck F, Fitzsimons C, et al. Sedentary  
26 Behavior in the First Year After Stroke: A Longitudinal Cohort Study With Objective Measures. *Arch*  
27 *Phys Med Rehabil*. 2015;96:15-23.
- 28 30. Fini NA, Holland AE, Keating J, Simek J, Bernhardt J. How physically active are people  
29 following stroke? Systematic review and quantitative synthesis. *Phys Ther*. 2017;97(Early Online):1-  
30 11.
- 31 31. Cereda C, Pezzoli G, Barichella M. Role of an Electronic Armband in Motor Function  
32 Monitoring in Patient's with Parkinson's Disease. *Nutrition*. 2010;26:240-2.
- 33 32. Troosters T, Sciruba F, Battaglia S, Langer D, Valluri S, Martino L, et al. Physical Inactivity in  
34 Patients with COPD, a Controlled Multi-Center Pilot Study. *Respir Med*. 2010;104:1005-11.
- 35 33. Camillo C, Pitta F, Possani H, Barbosa M, Marques D, Cavalheri V, et al. Heart Rate Variability  
36 and Disease Characteristics in Patients with COPD. *Lung*. 2008;186:393-401.
- 37 34. Moore SA, Hallsworth K, Bluck LJ, Ford GA, Rochester L, Trenell MI. Measuring energy  
38 expenditure after stroke: validation of a portable device. *Stroke; a journal of cerebral circulation*.  
39 2012;43(6):1660-2.
- 40 35. Vanroy C, Vissers D, Cras P, Beyne S, Feys H, Vanlandewijck Y, et al. Physical activity  
41 monitoring in stroke: SenseWear Pro2 Activity accelerometer versus Yamax Digi-Walker SW-200  
42 Pedometer. *Disabil Rehabil*. 2014;36(20):1695-703.
- 43 36. Wanklyn P, Ilsley DW, Greenstein D, Hampton IFG, Roper TA, Kester RC, et al. The cold  
44 hemiplegic arm. *Stroke*. 1994;25(9):1765-70.
- 45 37. Herrmann SD, Barreira TV, Kang M, Ainsworth BE. How Many Hours are Enough?  
46 Accelerometer Wear Time May Provide Bias in Daily Activity Estimates. *Journal of Physical Activity and*  
47 *Health*. 2013;10:742-9.
- 48 38. Mudge S, Stott NS. Test-retest reliability of the StepWatch Activity Monitor outputs in  
49 individuals with chronic stroke. *Clin Rehabil*. 2008;22(10-11):871-7.
- 50 39. Damen JAAG, Hooft L, Schuit E, Debray TPA, Collins GS, Tzoulaki I, et al. Prediction models  
51 for cardiovascular disease risk in the general population: systematic review. *BMJ*.  
52 2016;353(i2416):11 pages.
- 53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 40. National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute  
4 cardiovascular disease risk. 2009.  
5 41. National Vascular Disease Prevention Alliance. Guidelines for management of absolute  
6 cardiovascular disease risk. 2012.  
7 42. Hill K, Denisenko S, Miller K, Clements T, Batchelor F. Clinical outcome measurement in adult  
8 neurological physiotherapy 3rd ed. Melbourne: Australian Physiotherapy Association; 2005.  
9 43. O'Rourke S, MacHale S, Signorini D, Dennis M. Detecting psychiatric morbidity after stroke:  
10 comparison of the GHQ and the HAD Scale. *Stroke*. 1998;29(5):980-5.  
11 44. Tseng BY, Billinger SA, Gajewski BJ, Kluding PM. Exertion Fatigue and Chronic Fatigue are  
12 Two Distinct Constructs in People post Stroke. . *Stroke*. 2010;41:2908-12.  
13 45. Chiti G, Pantoni L. Use of Montreal Cognitive Assessment in Patients with Stroke. *Stroke*.  
14 2014;45:3135-40.  
15 46. Collin C, Wade DT, Davies S, Horne V. The Barthel Index: A Reliability Study. *Int Disabil Stud*.  
16 1988;10(2):61-3.  
17 47. Rimmer JH, Rauworth AE, Wang EC, Nicola TL, Hill B. A Preliminary Study to Examine the  
18 Effects of Aerobic and Therapeutic (Nonaerobic) Exercise on Cardiorespiratory Fitness and Coronary  
19 Risk Reduction in Stroke Survivors. *Arch Phys Med Rehabil*. 2009;90:407-12.  
20 48. Jorgenson JR, Bech-Pederson DT, Zeeman P, Sorenson J. Effect of Intensive Outpatient  
21 Physical Training on Gait Performance & CV Health in People with Hemiparesis After Stroke. . *Phys*  
22 *Ther*. 2010;90(4):527-38.  
23 49. Schoenfeld DA. Statistical considerations for clinical trials and scientific experiments  
24 Massachusetts: The Massachusetts General Hospital's Biostatistics Center; [cited 2011 05].  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Protocol for a Longitudinal Study into Physical Activity and Cardiovascular Risk in People with Stroke: Tables

Table 1: Assessment Time-points & Outcomes

Outcomes Measured	Baseline	6 months	12 months	24 months
Demographics	✓			
MVPA Duration	✓	✓	✓	✓
Other PA Outcomes	✓	✓	✓	✓
Fasting Lipid Profile & Plasma Glucose	✓		✓	✓
Blood Pressure, Waist Circumference & BMI	✓	✓	✓	✓
Mobility Measures	✓	✓	✓	✓
Questions Regarding Further Stroke and Cardiovascular Events		✓	✓	✓
Questions Regarding Cardiovascular Risk Factors & PA	✓	✓	✓	✓
HADS, FSS & MOCA	✓	✓	✓	✓
Self-Report Barthel Index	✓	✓	✓	✓

MVPA = moderate to vigorous physical activity; PA = physical activity; BMI = body mass index; HADS = hospital anxiety and depression scale; FSS = fatigue severity scale; MOCA = Montreal cognitive assessment

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	N/A Protocol
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any pre-specified hypotheses	7-9
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	9-10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	10-11
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	10-11
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-15
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-15
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	15-16
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	15-16
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	16-17
		(b) Describe any methods used to examine subgroups and interactions	16-17
		(c) Explain how missing data were addressed	N/A
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	N/A

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			N/A Protocol
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			N/A Protocol
Key results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	18

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).